Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kaitlin Large has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Orchestrating faster access to products of non-profit R&D: a case study of a novel regimen for drug-resistant tuberculosis

    by Suerie Moon, Marcela Cristina Fogaça Vieira, Kaitlin Large

    Introduction: Non-profit product development partnerships (PDPs) have succeeded in bringing nearly 80 new drugs, vaccines and diagnostics for neglected diseases through regulatory approval, but arrangements to ensure they reach patients are unclear since the usual commercial incentives do not apply. We conducted a case study of how unusually fast access was achieved to a new treatment regimen for drug-resistant tuberculosis (DR-TB) developed by the TB Alliance (TBA). Over 100 countries procured the regimen in quantities to reach 67% of global demand by 2024, 5 years after first regulatory approval and 2 years after the WHO recommended it for routine use. What interventions contributed to this rapid rollout, and what role did the PDP play? Methods: We analysed the academic and grey literature, internal documents from TBA, and conducted interviews with 21 key informants from 16 organisations. We identified relevant interventions and actors, constructed a timeline and analysed the role TBA played. Results: We found TBA orchestrated a complex set of interventions implemented by dozens of actors over an 8-year time period across three categories: regulatory and normative guidance; market shaping for affordability and availability; and supporting country-level implementation through knowledge generation, knowledge sharing, stakeholder engagement and advocacy. Five attributes enabled TBA to do so: ability to generate and share knowledge about the product and regimen; non-profit status; ability to mobilise material resources for access interventions; pre-existing relationships and/or ability to develop new collaborative relationships; and intrinsic motivation to see the product reaching people with DR-TB. Conclusion: An orchestrator able to steer many actors towards the shared goal of reaching patients is critical in a complex ecosystem where no single organisation can realise access alone. Non-profit product developers can play this role well, including managing actual or perceived conflicts of interest, but require clearer mandates and financial support to do so.

  • Open Access

    The 30-year evolution of oral cholera vaccines: A case study of a collaborative network alternative innovation model

    by Kaitlin Large, Adrian Alonso Ruiz, Iulia Slovenski, Marcela Vieira, Suerie Moon

    Cholera outbreaks have been rapidly increasing around the world. While long-term cholera prevention and control measures rely on improvements in water, sanitation, and hygiene, oral cholera vaccines (OCVs) are used for prevention and control in the short-to-medium term. OCVs lack the market incentives available in other more profitable disease areas. The development of OCVs was made possible through an alternative innovation model, which sustained innovation across multiple generations of the product for more than three decades. To examine how this alternative innovation model worked, we conducted 18 semi-structured interviews with key stakeholders related to the development of several OCVs, including “Dukoral”, “Shanchol”, and “Euvichol-Plus”, as well as additional cholera vaccines currently under development. Interview data was analyzed thematically according to the resources used by organizations (including funding, knowledge, relationships, and manufacturing), and the practices they implemented during each stage of the R&D process (including knowledge management and intellectual property strategies, approaches to transparency, and global access strategies). Next, we created participatory network maps to illustrate the structure of the relationships between stakeholders and how these evolved over time. We found that a core group of stakeholders were able to influence policies to promote the use of OCVs, and successfully develop, finance, and obtain WHO Prequalification for safe, effective, and affordable OCVs for global procurement and distribution. The evolution of OCVs demonstrates how a collaborative network innovation model can successfully develop new pharmaceutical products that are affordable and well-suited for use in context. This model could be applied to other areas of pharmaceutical innovation, such as pandemic preparedness, for more equitable outcomes for global public health.


  • Open Access

    Reforming the innovation system to deliver affordable medicines: a conceptual framework of pharmaceutical innovation as a complex adaptive system (forest) and theory of change

    by Suerie Moon, Adrian Alonso Ruiz, Marcela C. F. Vieira, Kaitlin E. Large, Iulia Slovenski

    The current mainstream pharmaceutical innovation system (PIS) is driven by the market-based logic of charging the highest prices societies will bear. Outcomes include unaffordable medicines, restricted access and pressure on health budgets. How can the innovation system change to deliver fairly-priced medicines? We inductively developed a novel conceptual framework of the PIS as a complex adaptive system (CAS) analogous to a forest. We constructed a database of 140 pharmaceutical innovation initiatives that sought to address global public interest objectives such as fair pricing or missing innovation. We found a critical mass of initiatives clustered around four areas: pandemic preparedness, neglected diseases, rare diseases and antibiotics, which we conceptualised as niches within the ecosystem. We reviewed the literature on how each niche had emerged and evolved, conducted interviews, and organised workshops with experts on each niche. Finally, we identified from the literature an initial list of ‘levers’ of change in the PIS, supplemented them with additional levers found in each niche, then compared across niches. We found that actors created niches in the broader system by purposefully problematising an issue, then pulling on one or more of three levers: mobilising new resources, changing the roles of or creating new actors, and/or changing societal norms or legal rules. A wide range of actors – including governments, funders, R&D practitioners, or civil society groups – could pull these levers, and the order in which they were pulled was not fixed, consistent with a CAS. Parts of the vast pharmaceutical innovation system have changed to deliver more affordable medicines by design. Such change has occurred largely within specialised niches, responding to evolving societal norms about the purpose of pharmaceutical innovation. Actors can achieve larger-scale change by further expanding and/or solidifying these niches through changes to resources, actor roles, norms and rules.


  • Open Access

    Alternative Pharmaceutical Innovation Models in Competitive Markets: A Collaborative Approach to Develop a Novel Drug for Hepatitis C

    by Marcela Vieira, Iulia Slovenski, Kaitlin Large, Adrian Alonso Ruiz, Suerie Moon

    Alternative innovation models have emerged to address failures of the traditional pharmaceutical system, particularly for diseases where market incentives do not attract sufficient research and development efforts. However, the feasibility of such models for diseases with significant markets is not well-established. This article analyses the development of a novel drug (ravidasvir) for the treatment of hepatitis C, a highly profitable market. Data from qualitative research methods, including literature reviews and semi-structured interviews, was analyzed using a novel conceptual framework focusing on actors, resources, organizational practices, and outcomes. Dissimilar to other projects, ravidasvir did not involve any major pharmaceutical companies. Rather, it leveraged the capacities of actors less traditionally involved in the development of novel medicines by constructing a collaborative network of private and public partners from low- and middle-income countries with a shared goal. The collaboration was successful in developing a highly effective, easy-to-use, and affordable medicine and contributed significantly to capacity-strengthening. However, the case also highlighted that strategic behavior by competing for-profit firms could pose significant challenges and that changing external conditions reduced the potential public health impact of the drug. Lessons from ravidasvir can inform future efforts to develop alternative innovation models for therapeutic areas with significant commercial interest.